David N Louis

List of Publications by Year in Descending Order

77 papers	28,489 citations	42 h-index	96 g-index
96 ext. papers	36,651 ext. citations	12.4 avg, IF	6.95 L-index

#	Paper	IF	Citations
77	Paul Kleihues (1936-2022), neuropathology innovator and entrepreneur.. *Brain Pathology*, **2022**, 32, e13073	6	
76	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. *Cell*, **2021**, 184, 1281-1298.e26	56.2	55
75	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology* , **2021**, 23, 1231-1251	1	708
74	Atretic cephalocele: Report of an infrequent dermatopathologic finding. *Journal of Cutaneous Pathology*, **2021**, 48, 1439-1441	1.7	0
73	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. *Brain Pathology*, **2020**, 30, 863-866	6	51
72	Roses and rosettes-the two sides of James Homer Wright. *Baylor University Medical Center Proceedings*, **2020**, 33, 286-292	0.6	
71	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathologica*, **2020**, 139, 603-608	14.3	170
70	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. *Journal of Infectious Diseases*, **2020**, 222, 1955-1959	7	39
69	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 196-206	5	9
68	A half century of change in diagnostic neuropathology: from the giants of yore to current brain tumor classification. *Human Pathology*, **2020**, 95, 161-168	3.7	0
67	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathology*, **2020**, 30, 844-856	6	196
66	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation. *Acta Neuropathologica*, **2019**, 137, 683-687	14.3	92
65	Characterization of applicants for residency training in pathology: Does diversity exist?. *Annals of Diagnostic Pathology*, **2019**, 40, 23-25	2.2	3
64	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell*, **2019**, 178, 835-849.e21	36.2	556
63	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. *Neuro-Oncology*, **2019**, 21, 596-605	1	13
62	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. *Nature Communications*, **2018**, 9, 810	17.4	42
61	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. *Acta Neuropathologica*, **2018**, 135, 639-642	14.3	186

60	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. *Science*, **2018**, 360, 331-335	33.3	255
59	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166	14.3	162
58	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). *Acta Neuropathologica*, **2018**, 135, 481-484	14.3	78
57	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. *Seminars in Neurology*, **2018**, 38, 19-23	3.2	18
56	Implementing the DICOM Standard for Digital Pathology. *Journal of Pathology Informatics*, **2018**, 9, 37	4.4	45
55	PATH-32. BRAIN TUMOR CLASSIFICATION UPDATES FROM cIMPACT-NOW, THE CONSORTIUM TO INFORM MOLECULAR AND PRACTICAL APPROACHES TO CNS TUMOR CLASSIFICATION. *Neuro-Oncology*, **2018**, 20, vi165-vi165	1	78
54	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. *Neuro-Oncology*, **2018**, 20, vi237-vi238	1	1
53	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathologica*, **2018**, 136, 805-810	14.3	367
52	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. *Neuro-Oncology*, **2017**, 19, 1380-1390	1	20
51	The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 189-194	3.1	1
50	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. *Science*, **2017**, 355,	33.3	455
49	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. *Neuro-Oncology*, **2017**, 19, 535-545	1	60
48	The 2016 WHO classification of central nervous system tumors: what neurologists need to know. *Current Opinion in Neurology*, **2017**, 30, 643-649	7.1	42
47	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO and Shakespeare. *Acta Neuropathologica*, **2017**, 134, 517-520	14.3	9
46	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. *Neuro-Oncology*, **2017**, 19, 1640-1650	1	36
45	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathology*, **2017**, 27, 851-852	6	36
44	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. *Neuro-Oncology*, **2017**, 19, 336-344	1	15
43	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). *Journal of Neuro-Oncology*, **2016**, 130, 31-42	4.8	29

42	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. *Nature*, **2016**, 539, 309-313	50.4	561
41	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. *Journal of Clinical Neuroscience*, **2016**, 31, 99-105	2.2	8
40	The flowering of pathology as a medical discipline in Boston, 1892-c.1950: W.T. Councilman, FB Mallory, JH Wright, SB Wolbach and their descendants. *Modern Pathology*, **2016**, 29, 944-61	9.8	2
39	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. *Journal of Neuropathology and Experimental Neurology*, **2016**, 75, 4-18	3.1	59
38	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	144
37	Angioleiomyoma of the falx. *Journal of Radiology Case Reports*, **2016**, 10, 8-15	1.1	4
36	Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. *New England Journal of Medicine*, **2016**, 375, 2381-2389	59.2	3
35	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, **2016**, 131, 803-20	14.3	8580
34	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discovery*, **2015**, 5, 1164-1177	24.4	581
33	The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. *Journal of Neuro-Oncology*, **2015**, 125, 531-49	4.8	29
32	Rapid Intraoperative Molecular Characterization of Glioma. *JAMA Oncology*, **2015**, 1, 662-7	13.4	53
31	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. *CNS Oncology*, **2015**, 4, 287-94	4	34
30	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. *Modern Pathology*, **2015**, 28, 596-606	9.8	43
29	Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. *Cell*, **2014**, 157, 580-94	56.2	549
28	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. *Nature Genetics*, **2014**, 46, 161-5	36.3	320
27	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. *Neuro-Oncology*, **2014**, 16, 1541-6	1	12
26	International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathology*, **2014**, 24, 429-35	6	408
25	Brain tumor cells in circulation are enriched for mesenchymal gene expression. *Cancer Discovery*, **2014**, 4, 1299-309	24.4	159

24	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science*, **2014**, 344, 1396-401	33.3	2401
23	The 2013 symposium on pathology data integration and clinical decision support and the current state of field. *Journal of Pathology Informatics*, **2014**, 5, 2	4.4	13
22	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.. *Journal of Clinical Oncology*, **2013**, 31, 2029-2029	2.2	1
21	Update on Glioma Treatments in the United States. *Japanese Journal of Neurosurgery*, **2013**, 22, 590-596	0	
20	An Ultra-High Speed Whole Slide Image Viewing System. *Analytical Cellular Pathology*, **2012**, 35, 65-73	3.4	7
19	Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. *Clinical Cancer Research*, **2009**, 15, 6430-7	12.9	72
18	The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathologica*, **2007**, 114, 97-109	14.3	8119
17	Molecular pathology of malignant gliomas. *Annual Review of Pathology: Mechanisms of Disease*, **2006**, 1, 97-117	34	478
16	Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. *Journal of Molecular Diagnostics*, **2006**, 8, 268-76	5.1	38
15	Focus on central nervous system neoplasia. *Cancer Cell*, **2002**, 1, 125-8	24.3	115
14	Clear cell pleomorphic xanthoastrocytoma: case report. *Acta Neuropathologica*, **2001**, 102, 404-8	14.3	6
13	Adult medulloblastoma: prognostic factors and patterns of relapse. *Neurosurgery*, **2000**, 47, 623-31; discussion 631-2	3.2	133
12	Multicolumn infusion of gene therapy cells into human brain tumors: technical report. *Neurosurgery* , **2000**, 46, 663-8; discussion 668-9	3.2	16
11	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. *Nature Medicine*, **1999**, 5, 881-7	50.5	278
10	Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. *Acta Neuropathologica*, **1998**, 95, 287-90	14.3	47
9	Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 857-65	3.1	73
8	Assignment of the human gene encoding eukaryotic initiation factor 4E (EIF4E) to the region q21-25 on chromosome 4. *Somatic Cell and Molecular Genetics*, **1997**, 23, 221-3		3
7	Glioblastoma multiforme in four siblings: a cytogenetic and molecular genetic study. *Journal of Neuro-Oncology*, **1995**, 24, 251-8	4.8	14

6	Evidence for subarachnoid spread in the development of multiple meningiomas. *Brain Pathology*, **1995**, 5, 11-4	6	28
5	Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. *Journal of Neuropathology and Experimental Neurology*, **1995**, 54, 91-5	3.1	266
4	The retinoblastoma gene is involved in malignant progression of astrocytomas. *Annals of Neurology* , **1994**, 36, 714-21	9.4	193
3	Subsets of glioblastoma multiforme defined by molecular genetic analysis. *Brain Pathology*, **1993**, 3, 19-26	6	520
2	Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. *Acta Neuropathologica*, **1993** , 86, 81-5	14.3	86
1	Mutant IDH Inhibitors Induce Lineage Differentiation in IDH-mutant Oligodendroglioma		1